Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Sep 6;19(9):e0309144.
doi: 10.1371/journal.pone.0309144. eCollection 2024.

Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis

Jilei Li  1 , Chenchen Zhang  2 , Yanchao Xu  1 , Lili Yang  3
Affiliations
Meta-Analysis

Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis

Jilei Li et al. PLoS One. .

Abstract

Purpose: This study aimed to assess the efficacy and safety of berberine(BBR) plus 5-aminosalicylic acid (5-ASA) for treating ulcerative colitis (UC).

Methods: A comprehensive search was conducted in electronic databases, including Medline/PubMed, Sinomed, Embase, CNKI, Wanfang, and VIP, through January 2024 to identify all randomized controlled trials (RCTs) that administered BBR conjunction in standard therapy(5-ASA) for to support the treatment of UC. The data were synthesized using a meta-analysis approach with RevMan 5.4.1. The primary endpoint was the clinical efficacy rate. In contrast, the secondary endpoints included the Baron score, disease activity index (DAI) score, symptom relief latency, inflammatory markers, immunological indicators, and adverse events.

Results: In this analysis, 10 RCTs comprising 952 patients with UC were examined. BBR considerably improved the clinical efficacy rate (RR = 1.22, 95% CI [1.15, 1.30], P < 0.00001), attenuated the Baron score (SMD = -1.72, 95% CI [-2.30, -1.13], P < 0.00001) and reduced the DAI score (SMD = -2.93, 95% CI [-4.42, -1.43], P < 0.00001). Additionally, it ameliorated clinical symptoms (SMD = -2.74, 95% CI [-3.45, 2.02], P < 0.00001), diminished inflammatory responses (SMD = -1.59, 95% CI [-2.14, 1.04], P < 0.00001), and modulated immune reactions (SMD = 1.06,95% CI [0.24,1.87], P <0.00001). Nonetheless, the impact of BBR on reducing adverse reactions was not statistically significant (RR = 0.75, 95% CI [0.42, 1.33], P > 0.05).

Conclusion: BBR demonstrates substantial efficacy in treating UC without causing severe adverse reactions and may serve as a viable complementary therapy. However, its clinical application warrants confirmation by additional high-quality, low-bias RCTs.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA flowchart of the study selection process.
Fig 2
Fig 2. Risk of bias summary.
Fig 3
Fig 3. Meta-analysis of clinical effective rate.
Fig 4
Fig 4. Meta-analysis of Baron score.
Fig 5
Fig 5. Meta-analysis of DAI score.
Fig 6
Fig 6. Meta-analysis of clinical symptoms.
Fig 7
Fig 7. Meta-analysis of inflammatory cytokines.
Fig 8
Fig 8. Meta-analysis of CD4+ T cells, CD8+ T cells, CD4+/CD8+ ratio.
Fig 9
Fig 9. Meta-analysis of adverse reactions.
Fig 10
Fig 10. Clinical effective rate funnel chart.
See this image and copyright information in PMC

References

    1. Gros B, Kaplan G G. Ulcerative Colitis in Adults: A Review[J]. JAMA, 2023,330(10):951–965. - PubMed
    1. Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis[J]. Lancet, 2023,402(10401):571–584. - PubMed
    1. Ng S C, Shi H Y, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]. Lancet, 2017,390(10114):2769–2778. - PubMed
    1. Singh S, Allegretti J R, Siddique S M, et al. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis[J]. Gastroenterology, 2020,158(5):1465–1496. - PMC - PubMed
    1. Kucharzik T, Koletzko S, Kannengiesser K, et al. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms[J]. Dtsch Arztebl Int, 2020,117(33–34):564–574. - PMC - PubMed

MeSH terms